Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review.
Adverse events
Anti-vascular endothelial growth factor
Complications
Laser photocoagulation
Retinopathy of prematurity
Journal
International ophthalmology
ISSN: 1573-2630
Titre abrégé: Int Ophthalmol
Pays: Netherlands
ID NLM: 7904294
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
07
02
2022
accepted:
20
08
2022
medline:
29
3
2023
pubmed:
11
10
2022
entrez:
10
10
2022
Statut:
ppublish
Résumé
To synthesize existing evidence on adverse events, complications, and unfavorable outcomes of current treatment modalities for treatment-requiring retinopathy of prematurity (TR-ROP). PubMed, Cochrane Central Register of Controlled Trials, Scopus, EMBASE, Trip Database, and the gray literature available were searched. Randomized Clinical Trials and observational studies comparing the adverse events of intravitreal anti-VEGF injections (bevacizumab, ranibizumab, aflibercept, pegaptanib, conbercept) and laser photocoagulation (LPC) as treatment modalities for infants with TR-ROP were included. The main outcomes compared between the two treatment modalities were: 1. Refractive Errors and Biometry Parameters, 2. Adverse events, complications, and unfavorable outcomes, 3. Disease Recurrence/Disease Regression/Need for retreatment, 4. Neurodevelopmental Outcomes. Higher quality studies concluded that LPC leads to greater rates of myopia than intravitreal anti-VEGF treatment while the rate of adverse events and of unfavorable neurodevelopmental outcomes is similar. However, there was controversy among the included studies concerning the rate of ROP recurrence between intravitreal anti-VEGF injections and LPC. There is need for future primary studies assessing the adverse events of intravitreal anti-VEGF injections compared with LPC as treatment modalities for infants with TR-ROP.
Identifiants
pubmed: 36214992
doi: 10.1007/s10792-022-02480-6
pii: 10.1007/s10792-022-02480-6
pmc: PMC10042936
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Bevacizumab
2S9ZZM9Q9V
Ranibizumab
ZL1R02VT79
Vascular Endothelial Growth Factor A
0
Types de publication
Comparative Study
Journal Article
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1027-1062Informations de copyright
© 2022. The Author(s).
Références
J Curr Ophthalmol. 2018 Nov 09;31(1):61-65
pubmed: 30899848
Ophthalmic Surg Lasers Imaging Retina. 2018 Feb 1;49(2):126-131
pubmed: 29443362
Retina. 2020 Sep;40(9):1793-1803
pubmed: 31800460
J AAPOS. 2018 Feb;22(1):61-65.e1
pubmed: 29223789
Acta Ophthalmol. 2014 Sep;92(6):e496-7
pubmed: 24428792
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
Invest Ophthalmol Vis Sci. 2015 Jan 22;56(2):956-61
pubmed: 25613938
Ophthalmol Retina. 2018 Sep;2(9):942-948
pubmed: 31047228
J Perinatol. 2019 Sep;39(9):1300-1308
pubmed: 31341226
Pediatrics. 2016 Apr;137(4):
pubmed: 27244705
Curr Eye Res. 2017 Jul;42(7):1054-1058
pubmed: 28128986
Ophthalmol Retina. 2020 Dec;4(12):1202-1208
pubmed: 32512055
Arch Ophthalmol. 1988 Apr;106(4):463-4
pubmed: 3281639
PLoS One. 2020 Mar 20;15(3):e0230678
pubmed: 32196539
JAMA Ophthalmol. 2014 Nov;132(11):1327-33
pubmed: 25103848
PLoS One. 2016 Jan 27;11(1):e0148019
pubmed: 26815000
Br J Ophthalmol. 2020 May;104(5):691-696
pubmed: 31420328
Korean J Ophthalmol. 2019 Jun;33(3):272-278
pubmed: 31179659
Graefes Arch Clin Exp Ophthalmol. 2017 Feb;255(2):263-269
pubmed: 27495302
Ophthalmology. 2015 May;122(5):1008-15
pubmed: 25687024
Arq Bras Oftalmol. 2015 Sep-Oct;78(5):300-4
pubmed: 26466229
J AAPOS. 2015 Apr;19(2):140-4
pubmed: 25892041
Am J Ophthalmol. 2013 Jun;155(6):1119-1124.e1
pubmed: 23490192
Arch Soc Esp Oftalmol. 2017 Oct;92(10):472-476
pubmed: 28624314
Taiwan J Ophthalmol. 2018 Oct-Dec;8(4):243-248
pubmed: 30637196
Br J Ophthalmol. 2019 Sep;103(9):1332-1336
pubmed: 30514709
Ophthalmology. 2016 Oct;123(10):2166-75
pubmed: 27506484
N Engl J Med. 2011 Feb 17;364(7):603-15
pubmed: 21323540
Lancet. 2019 Oct 26;394(10208):1551-1559
pubmed: 31522845
Can J Ophthalmol. 2021 Jun;56(3):179-183
pubmed: 33160917
PLoS One. 2016 Aug 22;11(8):e0161692
pubmed: 27548628
Open Med. 2009;3(3):e123-30
pubmed: 21603045
Cardiovasc J Afr. 2020 May/Jun 23;31(3):123-129
pubmed: 31995115
Am J Ophthalmol. 2018 Aug;192:20-30
pubmed: 29753851
Med Sci Monit. 2016 Apr 10;22:1192-209
pubmed: 27062023
Arch Ophthalmol. 2012 Jun;130(6):800-1
pubmed: 22801850
Curr Eye Res. 2017 Mar;42(3):462-469
pubmed: 27420302
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
Acta Ophthalmol. 2016 Sep;94(6):e417-20
pubmed: 27009449
Ophthalmologica. 2015;234(4):211-7
pubmed: 26393895
Br J Ophthalmol. 2017 Mar;101(3):365-370
pubmed: 27301450
Am J Ophthalmol. 2020 Oct;218:208-213
pubmed: 32450064
J AAPOS. 2019 Oct;23(5):264.e1-264.e4
pubmed: 31521847
Retina. 2017 Apr;37(4):710-717
pubmed: 27529839
Strabismus. 2016 Jun;24(2):84-8
pubmed: 27120579
Ophthalmologe. 2018 Jun;115(6):476-488
pubmed: 29637302
J AAPOS. 2019 Oct;23(5):260.e1-260.e4
pubmed: 31513902
Semin Perinatol. 2019 Oct;43(6):315-316
pubmed: 31151777
BMC Ophthalmol. 2019 Feb 26;19(1):60
pubmed: 30808338
Ophthalmology. 2018 Feb;125(2):218-226
pubmed: 28867130
Ophthalmology. 2001 Jun;108(6):1013-4
pubmed: 11382621